Roseoside

Roseoside potently inhibits the growth of Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Bacillus subtilis, and Candida albicans with MIC values of 4.53 µM, 9.05 µM, 3.23 µM, 5.56 µM, and 2.59 µM, respectively^[1].
Roseoside (31.25-1000 µg/mL) exhibits low cytotoxicity toward Vero cells, with an IC₅₀ of 591.50 µg/mL and a maximum non-toxic concentration of 250 µg/mL^[1].
Roseoside exhibits favorable in silico ADME properties, including moderate gastrointestinal absorption, no blood-brain barrier permeability, and a bioavailability score of 0.55, supporting its potential as an orally bioactive agent^[1].
Roseoside (40 μM; 48 h) significantly inhibits HCV infection in naïve Huh7.5 cells, reducing relative HCV RNA levels to 48% of the control^[2].
Roseoside (5-40 μM; 48 h) inhibits HCV infection in naïve Huh7.5 cells in vitro in a concentration-dependent manner (EC₅₀ = 38.92 μM over 48 h) with no marked cytotoxicity at concentrations ≤40 μM^[2].
Roseoside (40 μM; maintained from 4 h post-inoculation) inhibits HCV replication in naïve Huh7.5 cells in a time-dependent manner, reducing intracellular HCV RNA to 62% and 49% of the control at 36 and 48 h post-inoculation, respectively^[2].
Roseoside (20-40 μM; 15 min pre-incubation at room temperature, followed by 1 h reaction) inhibits HCV NS5A/B replicase activity in vitro, reducing activity to 50% and 45% of the control at concentrations of 20 μM and 40 μM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.